Matthieu Perreau

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


109 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2002 |
 
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study.
Abela I.A., Hauser A., Schwarzmüller M., Pasin C., Kusejko K., Epp S., Cavassini M., Battegay M., Rauch A., Calmy A. et al., 2024/08/16. The Journal of infectious diseases, 230 (2) pp. e292-e304. Peer-reviewed.
 
Immunological and Haematological Relevance of Helminths and Mycobacterium tuberculosis Complex Coinfection among Newly Diagnosed Pulmonary Tuberculosis Patients from Bobo-Dioulasso, Burkina Faso.
Djibougou D.A., Mensah G.I., Kaboré A., Toé I., Sawadogo L.T., Lompo P.F., Kone AMM, Hien H., Meda C.Z., Combary A. et al., 2024/07/03. Biomedicines, 12 (7). Peer-reviewed.
 
Editorial introduction
Debyser Zeger, Perreau Matthieu, Kaufmann Daniel, 2024/05. Current Opinion in HIV and AIDS, 19 (3) pp. v-vi.
The multifaceted nature of HIV tissue reservoirs.
Banga R., Perreau M., 2024/05/01. Current opinion in HIV and AIDS, 19 (3) pp. 116-123. Peer-reviewed.
Die Bedeutung des QuantiFERON Gold Plus-Tests für die Diagnose der vermuteten Augentuberkulose [The Importance of QuantiFERON Gold Plus Test for the Diagnosis of Presumed Ocular Tuberculosis]
Bruzzone F., Plebani M., Koryllou A., Perreau M., Guex-Crosier Y., 2024/04. Klinische Monatsblatter fur Augenheilkunde, 241 (4) pp. 432-434. Peer-reviewed.
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
Gasca-Capote C., Lian X., Gao C., Roseto I.C., Jiménez-León M.R., Gladkov G., Camacho-Sojo M.I., Pérez-Gómez A., Gallego I., Lopez-Cortes L.E. et al., 2024/02/20. The Journal of clinical investigation, 134 (8). Peer-reviewed.
Myeloid-Derived Suppressor-like Cells as a Prognostic Marker in Critically Ill Patients: Insights from Experimental Endotoxemia and Intensive Care Patients.
Schrijver I.T., Herderschee J., Théroude C., Kritikos A., Leijte G., Le Roy D., Brochut M., Chiche J.D., Perreau M., Pantaleo G. et al., 2024/02/08. Cells, 13 (4). Peer-reviewed.
 
Editorial: Understanding convergent evasion mechanisms in cancer and chronic infection: implications for immunotherapy.
Echchannaoui H., Perreau M., Schild H., Theobald M., 2024. Frontiers in immunology, 15 p. 1450555. Peer-reviewed.
 
Self-reported neurocognitive complaints in the Swiss HIV Cohort Study: a viral genome-wide association study.
Zeeb M., Pasin C., Cavassini M., Bieler-Aeschlimann M., Frischknecht P., Kusejko K., Fellay J., Blanquart F., Metzner K.J., Neumann K. et al., 2024. Brain communications, 6 (4) pp. fcae188. Peer-reviewed.
Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART.
Banga R., Procopio F.A., Lana E., Gladkov G.T., Roseto I., Parsons E.M., Lian X., Armani-Tourret M., Bellefroid M., Gao C. et al., 2023/10/11. Cell host & microbe, 31 (10) pp. 1714-1731.e9. Peer-reviewed.
Correction to: New Dominant‑Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130‑Dependent Hyper‑IgE Syndrome.
Arlabosse T., Materna M., Riccio O., Schnider C., Angelini F., Perreau M., Rochat I., Superti-Furga A., Campos-Xavier B., Héritier S. et al., 2023/10. Journal of clinical immunology, 43 (7) p. 1674. Peer-reviewed.
New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome.
Arlabosse T., Materna M., Riccio O., Schnider C., Angelini F., Perreau M., Rochat I., Superti-Furga A., Campos-Xavier B., Héritier S. et al., 2023/10. Journal of clinical immunology, 43 (7) pp. 1566-1580. Peer-reviewed.
Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
Dumusc A., Alromaih F., Perreau M., Hügle T., Zufferey P., Dan D., 2023/06/01. Arthritis research & therapy, 25 (1) p. 91. Peer-reviewed.
 
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1.
Balakrishna S., Loosli T., Zaheri M., Frischknecht P., Huber M., Kusejko K., Yerly S., Leuzinger K., Perreau M., Ramette A. et al., 2023/03/02. The Journal of antimicrobial chemotherapy, 78 (3) pp. 656-664. Peer-reviewed.
 
Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach.
Labarile M., Loosli T., Zeeb M., Kusejko K., Huber M., Hirsch H.H., Perreau M., Ramette A., Yerly S., Cavassini M. et al., 2023/02/14. The Journal of infectious diseases, 227 (4) pp. 554-564. Peer-reviewed.
SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection.
Jacot D., von Rotz U., Pellaton C., Blondet F., Aebischer O., Perreau M., De Rham M., Pantaleo G., Marchetti O., Greub G., 2023. Microbes and infection, 25 (1-2) p. 105077. Peer-reviewed.
CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses.
Noto A., Joo V., Mancarella A., Suffiotti M., Pellaton C., Fenwick C., Perreau M., Pantaleo G., 2022/11/28. Viruses, 14 (12) p. 2665. Peer-reviewed.
Host Molecule Incorporation into HIV Virions, Potential Influences in HIV Pathogenesis.
Munoz O., Banga R., Perreau M., 2022/11/14. Viruses, 14 (11). Peer-reviewed.
COVID-19 rapidly increases MDSCs and prolongs innate immune dysfunctions.
Schrijver I.T., Théroude C., Antonakos N., Regina J., Le Roy D., Bart P.A., Chiche J.D., Perreau M., Pantaleo G., Calandra T. et al., 2022/10. European journal of immunology, 52 (10) pp. 1676-1679. Peer-reviewed.
 
A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort Study.
Chaudron S.E., Leemann C., Kusejko K., Nguyen H., Tschumi N., Marzel A., Huber M., Böni J., Perreau M., Klimkait T. et al., 2022/09/28. The Journal of infectious diseases, 226 (7) pp. 1256-1266. Peer-reviewed.
Magnitude and associated factors of latent tuberculosis infection due to Mycobacterium tuberculosis complex among high-risk groups in urban Bobo-Dioulasso, Burkina Faso.
Djibougou D.A., Mensah G.I., Sagna T., Sawadogo L.T., Ouedraogo A.K., Kabore A., Hien H., Meda C.Z., Combary A., Belem A.M. et al., 2022/09. IJID regions, 4 pp. 1-9. Peer-reviewed.
Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort.
Menges D., Zens K.D., Ballouz T., Caduff N., Llanas-Cornejo D., Aschmann H.E., Domenghino A., Pellaton C., Perreau M., Fenwick C. et al., 2022/08/18. Nature communications, 13 (1) p. 4855. Peer-reviewed.
A Phylogeny-aware GWAS Framework to Correct for Heritable Pathogen Effects on Infectious Disease Traits.
Nadeau S., Thorball C.W., Kouyos R., Günthard H.F., Böni J., Yerly S., Perreau M., Klimkait T., Rauch A., Hirsch H.H. et al., 2022/08/03. Molecular biology and evolution, 39 (8) pp. msac163. Peer-reviewed.
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics.
Kusejko K., Tschumi N., Chaudron S.E., Nguyen H., Battegay M., Bernasconi E., Böni J., Huber M., Calmy A., Cavassini M. et al., 2022/08/01. Journal of acquired immune deficiency syndromes, 90 (4) pp. e4-e12. Peer-reviewed.
 
Correction to: Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group.
Nguyen H., Hampel B., Nuñez D.G., Battegay M., Hachfeld A., Bernasconi E., Calmy A., Cavassini M., Vernazza P., Fellay J. et al., 2022/07/06. Clinical infectious diseases, 74 (12) p. 2266. Peer-reviewed.
Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells.
Munoz O., Banga R., Schelling R., Procopio F.A., Mastrangelo A., Nortier P., Ohmiti K., Daraspe J., Cavassini M., Fenwick C. et al., 2022/07. PLoS pathogens, 18 (7) pp. e1010673. Peer-reviewed.
Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19.
Kritikos A., Gabellon S., Pagani J.L., Monti M., Bochud P.Y., Manuel O., Coste A., Greub G., Perreau M., Pantaleo G. et al., 2022/05/18. Viruses, 14 (5) p. 1089. Peer-reviewed.
 
Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group.
Nguyen H., Hampel B., Garcia Nuñez D., Battegay M., Hachfeld A., Bernasconi E., Calmy A., Cavassini M., Vernazza P., Fellay J. et al., 2022/04/28. Clinical infectious diseases, 74 (8) pp. 1468-1475. Peer-reviewed.
 
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS).
Scherrer A.U., Traytel A., Braun D.L., Calmy A., Battegay M., Cavassini M., Furrer H., Schmid P., Bernasconi E., Stoeckle M. et al., 2022/02/18. International journal of epidemiology, 51 (1) pp. 33-34j. Peer-reviewed.
 
Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study.
Duran Ramirez J.J., Ballouz T., Nguyen H., Kusejko K., Chaudron S.E., Huber M., Hirsch H.H., Perreau M., Ramette A., Yerly S. et al., 2022/01/18. The Journal of infectious diseases, 225 (2) pp. 306-316. Peer-reviewed.
The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection.
Noto A., Suffiotti M., Joo V., Mancarella A., Procopio F.A., Cavet G., Leung Y., Corpataux J.M., Cavassini M., Riva A. et al., 2022. Frontiers in immunology, 13 p. 960120. Peer-reviewed.
 
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
Pyngottu A., Scherrer A.U., Kouyos R., Huber M., Hirsch H., Perreau M., Yerly S., Calmy A., Cavassini M., Stöckle M. et al., 2021/10/05. Clinical infectious diseases, 73 (7) pp. e2134-e2141. Peer-reviewed.
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S., Latifyan S., Fenwick C., Bouchaab H., Suffiotti M., Moslehi J.J., Salem J.E., Schaefer N., Nicod-Lalonde M., Costes J. et al., 2021/10. Journal for immunotherapy of cancer, 9 (10) pp. e003594. Peer-reviewed.
 
Immunological Assessment of Pediatric Multisystem Inflammatory Syndrome Related to Coronavirus Disease 2019.
Grazioli S., Tavaglione F., Torriani G., Wagner N., Rohr M., L'Huillier A.G., Leclercq C., Perrin A., Bordessoule A., Beghetti M. et al., 2021/08/14. Journal of the Pediatric Infectious Diseases Society, 10 (6) pp. 706-713. Peer-reviewed.
The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients.
Perreau M., Suffiotti M., Marques-Vidal P., Wiedemann A., Levy Y., Laouénan C., Ghosn J., Fenwick C., Comte D., Roger T. et al., 2021/08/09. Nature communications, 12 (1) p. 4888. Peer-reviewed.
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.
Lévy Y., Wiedemann A., Hejblum B.P., Durand M., Lefebvre C., Surénaud M., Lacabaratz C., Perreau M., Foucat E., Déchenaud M. et al., 2021/07/23. iScience, 24 (7) p. 102711. Peer-reviewed.
HIV persistence in lymph nodes.
Banga R., Munoz O., Perreau M., 2021/07/01. Current opinion in HIV and AIDS, 16 (4) pp. 209-214. Peer-reviewed.
 
Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men.
Bachmann N., Kusejko K., Nguyen H., Chaudron S.E., Kadelka C., Turk T., Böni J., Perreau M., Klimkait T., Yerly S. et al., 2021/06/15. Clinical infectious diseases, 72 (12) pp. 2175-2183. Peer-reviewed.
Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link.
Nguyen H., Thorball C.W., Fellay J., Böni J., Yerly S., Perreau M., Hirsch H.H., Kusejko K., Thurnheer M.C., Battegay M. et al., 2021/06/01. eLife, 10. Peer-reviewed.
 
Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission.
Reichmuth M.L., Chaudron S.E., Bachmann N., Nguyen H., Böni J., Metzner K.J., Perreau M., Klimkait T., Yerly S., Hirsch H.H. et al., 2021/05. HIV medicine, 22 (5) pp. 346-359. Peer-reviewed.
 
Chimeric antigen receptor T-cell therapy for HIV cure.
Alfageme-Abello O., Porret R., Perreau M., Perez L., Muller Y.D., 2021/03/01. Current opinion in HIV and AIDS, 16 (2) pp. 88-97. Peer-reviewed.
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L., Bouchaab H., Mederos N., Nguyen-Ngoc T., Perreau M., Fenwick C., Vaucher J., Sempoux C., Peters S., Obeid M., 2021/02. Journal of thoracic oncology, 16 (2) pp. 318-326. Peer-reviewed.
Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers.
Tumbo A.M., Schindler T., Dangy J.P., Orlova-Fink N., Bieri J.R., Mpina M., Milando F.A., Juma O., Hamad A., Nyakarungu E. et al., 2021/01/26. Virology journal, 18 (1) p. 28. Peer-reviewed.
 
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
Özdemir B.C., Latifyan S., Perreau M., Fenwick C., Alberio L., Waeber G., Spertini F., de Leval L., Michielin O., Obeid M., 2020/12. Annals of oncology, 31 (12) pp. 1775-1778. Peer-reviewed.
 
Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment.
Thorball C.W., Borghesi A., Bachmann N., Von Siebenthal C., Vongrad V., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Roth V. et al., 2020/12/01. Journal of acquired immune deficiency syndromes, 85 (4) pp. 517-524. Peer-reviewed.
Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART.
Wan C., Bachmann N., Mitov V., Blanquart F., Céspedes S.P., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Fellay J. et al., 2020/11/02. Nature communications, 11 (1) p. 5542. Peer-reviewed.
 
Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy.
Kuo H.H., Banga R., Lee G.Q., Gao C., Cavassini M., Corpataux J.M., Blackmer J.E., Zur Wiesch S., Yu X.G., Pantaleo G. et al., 2020/07/23. The Journal of infectious diseases, 222 (4) pp. 655-660. Peer-reviewed.
A case report on the cytokine signature profile of immunoglobulin G4-related disease.
Dällenbach J., Moi L., Humair G., Letovanec I., Perreau M., Cherix S., Comte D., Vaucher J., 2020/07. Scandinavian journal of rheumatology, 49 (4) pp. 332-333. Peer-reviewed.
 
Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients.
Abela I.A., Scherrer A.U., Böni J., Yerly S., Klimkait T., Perreau M., Hirsch H.H., Furrer H., Calmy A., Schmid P. et al., 2020/01/02. Clinical infectious diseases, 70 (2) pp. 297-303. Peer-reviewed.
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.
Vigano S., Bobisse S., Coukos G., Perreau M., Harari A., 2020. Frontiers in immunology, 11 p. 1350. Peer-reviewed.
 
Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018.
Kusejko K., Marzel A., Nguyen H., Chaudron S.E., Bachmann N., Weber R., Bruggmann P., Roth J.A., Bernasconi E., Calmy A. et al., 2020. Antiviral therapy, 25 (1) pp. 43-54. Peer-reviewed.
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.
Giel-Moloney M., Esteban M., Oakes B.H., Vaine M., Asbach B., Wagner R., Mize G.J., Spies A.G., McElrath J., Perreau M. et al., 2019/12/27. Scientific reports, 9 (1) p. 20005. Peer-reviewed.
T-cell exhaustion in HIV infection.
Fenwick C., Joo V., Jacquier P., Noto A., Banga R., Perreau M., Pantaleo G., 2019/11. Immunological reviews, 292 (1) pp. 149-163. Peer-reviewed.
 
HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected.
Nguyen H., Thorball C.W., Fellay J., Böni J., Yerly S., Perreau M., Klimkait T., Kusejko K., Bachmann N., Chaudron S.E. et al., 2019/08/15. Journal of acquired immune deficiency syndromes, 81 (5) pp. 508-515. Peer-reviewed.
Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.
Bachmann N., von Siebenthal C., Vongrad V., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Fellay J., Roth V., Kok Y.L. et al., 2019/07/19. Nature communications, 10 (1) p. 3193. Peer-reviewed.
 
Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection.
Carlisle L.A., Turk T., Kusejko K., Metzner K.J., Leemann C., Schenkel C.D., Bachmann N., Posada S., Beerenwinkel N., Böni J. et al., 2019/06/19. The Journal of infectious diseases, 220 (2) pp. 254-265. Peer-reviewed.
HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses.
Amelio P., Portevin D., Hella J., Reither K., Kamwela L., Lweno O., Tumbo A., Geoffrey L., Ohmiti K., Ding S. et al., 2019/03/01. Journal of virology, 93 (5). Peer-reviewed.
 
Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.
Bachmann N., von Braun A., Labhardt N.D., Kadelka C., Günthard H.F., Sekaggya-Wiltshire C., Castelnuovo B., Kambugu A., Lejone T.I., Böni J. et al., 2019/02/01. The Journal of antimicrobial chemotherapy, 74 (2) pp. 468-472. Peer-reviewed.
A Rare Case of Diffuse Polyarthritis in the Context of an Epididymoorchitis due to Mumps Infection
Van Singer M., Felix N., Perreau M., Lebowitz D., Comte D., 2019. Rheumatology: Current Research, 09 (02). Peer-reviewed.
 
Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.
Kusejko K., Marzel A., Hampel B., Bachmann N., Nguyen H., Fehr J., Braun D.L., Battegay M., Bernasconi E., Calmy A. et al., 2018/11. HIV medicine, 19 (10) pp. 688-697. Peer-reviewed.
CD32+ and PD-1+ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals
Noto A., Procopio F.A., Banga R., Suffiotti M., Corpataux J.M., Cavassini M., Riva A., Fenwick C., Gottardo R., Perreau M. et al., 2018/10/15. Journal of virology, 92 (20). Peer-reviewed.
Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015.
Lazzarino T., Martenet S., Mamin R., Du Pasquier R.A., Peters S., Perreau M., Muller O., Hugli O., Cavassini M., Darling KEA, 2018/10/03. BMJ open, 8 (10) pp. e021203. Peer-reviewed.
 
Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.
Mombelli M., Rettby N., Perreau M., Pascual M., Pantaleo G., Manuel O., 2018/10/01. Vaccine, 36 (41) pp. 6163-6169. Peer-reviewed.
 
TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.
Cheng L., Wang Q., Li G., Banga R., Ma J., Yu H., Yasui F., Zhang Z., Pantaleo G., Perreau M. et al., 2018/10/01. The Journal of clinical investigation, 128 (10) pp. 4387-4396. Peer-reviewed.
Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells.
Tran TTP, Eichholz K., Amelio P., Moyer C., Nemerow G.R., Perreau M., Mennechet FJD, Kremer E.J., 2018/08. PLoS pathogens, 14 (8) pp. e1007127. Peer-reviewed.
Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.
Kusejko K., Kadelka C., Marzel A., Battegay M., Bernasconi E., Calmy A., Cavassini M., Hoffmann M., Böni J., Yerly S. et al., 2018/07. Virus evolution, 4 (2) pp. vey024. Peer-reviewed.
Hyperglycaemia is inversely correlated with live M. bovis BCG-specific CD4+ T cell responses in Tanzanian adults with latent or active tuberculosis
Boillat-Blanco N., Tumbo A.N., Perreau M., Amelio P., Ramaiya K.L., Mganga M., Schindler C., Gagneux S., Reither K., Probst-Hensch N. et al., 2018/06. Immunity, inflammation and disease, 6 (2) pp. 345-353. Peer-reviewed.
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.
Marzel A., Kusejko K., Weber R., Bruggmann P., Rauch A., Roth J.A., Bernasconi E., Calmy A., Cavassini M., Hoffmann M. et al., 2018/05. Open forum infectious diseases, 5 (5) pp. ofy078. Peer-reviewed.
Blood CXCR3 (+) CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals.
Banga R., Procopio F.A., Ruggiero A., Noto A., Ohmiti K., Cavassini M., Corpataux J.M., Paxton W.A., Pollakis G., Perreau M., 2018. Frontiers in immunology, 9 p. 144. Peer-reviewed.
IRF5 Is a Key Regulator of Macrophage Response to Lipopolysaccharide in Newborns.
Schneider A., Weier M., Herderschee J., Perreau M., Calandra T., Roger T., Giannoni E., 2018. Frontiers in immunology, 9 p. 1597. Peer-reviewed.
 
High titers of ADAbs in rheumatic disease patients undergoing anti-TNF therapy is not associated with lupus-like autoimmunity.
Safran A., Perreau M., So A., Zufferey P., 2017/12. Lupus, 26 (14) pp. 1571-1572. Peer-reviewed.
 
Targeted Immune Interventions for an HIV-1 Cure.
Perreau M., Banga R., Pantaleo G., 2017/10. Trends in molecular medicine, 23 (10) pp. 945-961. Peer-reviewed.
Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania.
Amelio P., Portevin D., Reither K., Mhimbira F., Mpina M., Tumbo A., Nickel B., Marti H., Knopp S., Ding S. et al., 2017/07. PLoS neglected tropical diseases, 11 (7) pp. e0005817. Peer-reviewed.
 
Current approaches to assess HIV-1 persistence.
Banga R., Procopio F.A., Perreau M., 2016/07. Current opinion in HIV and AIDS, 11 (4) pp. 424-431. Peer-reviewed.
 
PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals.
Banga R., Procopio F.A., Noto A., Pollakis G., Cavassini M., Ohmiti K., Corpataux J.M., de Leval L., Pantaleo G., Perreau M., 2016/07. Nature medicine, 22 (7) pp. 754-761. Peer-reviewed.
 
Strategies for targeting residual HIV infection.
Chomont N., Perreau M., 2016/07. Current opinion in HIV and AIDS, 11 (4) pp. 359-361. Peer-reviewed.
 
IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation.
Fellmann F., Angelini F., Wassenberg J., Perreau M., Arenas Ramirez N., Simon G., Boyman O., Demaria O., Christen-Zaech S., Hohl D. et al., 2016. Journal of Allergy and Clinical Immunology, 137 (4) pp. 1189-96.e1-2. Peer-reviewed.
Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human Dendritic Cells.
Eichholz K., Bru T., Tran T.T., Fernandes P., Welles H., Mennechet F.J., Manel N., Alves P., Perreau M., Kremer E.J., 2016. Plos Pathogens, 12 (9) pp. e1005871. Peer-reviewed.
Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis.
Rozot V., Patrizia A., Vigano S., Mazza-Stalder J., Idrizi E., Day C.L., Perreau M., Lazor-Blanchet C., Ohmiti K., Goletti D. et al., 2015. Clinical Infectious Diseases, 60 (3) pp. 432-437. Peer-reviewed.
High level of anti-drug antibodies after intra-articular injection of anti-TNF.
Zufferey P., Perreau M., So A., 2015. Rheumatology, 54 (12) pp. 2291-2292.
 
NBAS mutations cause a multisystem disorder involving bone, connective tissue, liver, immune system, and retina.
Segarra N.G., Ballhausen D., Crawford H., Perreau M., Campos-Xavier B., van Spaendonck-Zwarts K., Vermeer C., Russo M., Zambelli P.Y., Stevenson B. et al., 2015. American Journal of Medical Genetics. Part A, 167A (12) pp. 2902-2912. Peer-reviewed.
CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression.
Viganò S., Banga R., Bellanger F., Pellaton C., Farina A., Comte D., Harari A., Perreau M., 2014. Plos Pathogens, 10 (9) pp. e1004380. Peer-reviewed.
Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders.
Perreau M., Vigano S., Bellanger F., Pellaton C., Buss G., Comte D., Roger T., Lacabaratz C., Bart P.A., Levy Y. et al., 2014. Journal of Experimental Medicine, 211 (10) pp. 2033-2045. Peer-reviewed.
The dysfunction of T follicular helper cells.
Cubas R., Perreau M., 2014. Current Opinion In Hiv and Aids, 9 (5) pp. 485-491. Peer-reviewed.
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production.
Perreau M., Savoye A.L., De Crignis E., Corpataux J.M., Cubas R., Haddad E.K., De Leval L., Graziosi C., Pantaleo G., 2013. Journal of Experimental Medicine, 210 (1) pp. 143-156. Peer-reviewed.
 
Immune response to HIV.
Perreau M., Levy Y., Pantaleo G., 2013. Current Opinion in HIV and Aids, 8 (4) pp. 333-340.
Inadequate T follicular cell help impairs B cell immunity during HIV infection.
Cubas R.A., Mudd J.C., Savoye A.L., Perreau M., van Grevenynghe J., Metcalf T., Connick E., Meditz A., Freeman G.J., Abesada-Terk G. et al., 2013. Nature Medicine, 19 (4) pp. 494-499. Peer-reviewed.
 
Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4(+) T cells in active disease.
Perreau M., Rozot V., Welles H.C., Belluti-Enders F., Vigano S., Maillard M., Dorta G., Mazza-Stalder Jesica, Bart P.A., Roger T. et al., 2013. European Journal of Immunology, 43 (4) pp. 939-948.
 
Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.
Rozot V., Vigano S., Mazza-Stalder J., Idrizi E., Day C.L., Perreau M., Lazor-Blanchet C., Petruccioli E., Hanekom W., Goletti D. et al., 2013. European Journal of Immunology, 43 (6) pp. 1568-1577.
Rapid Perturbation in Viremia Levels Drives Increases in Functional Avidity of HIV-specific CD8 T Cells.
Viganò S., Bellutti Enders F., Miconnet I., Cellerai C., Savoye A.L., Rozot V., Perreau M., Faouzi M., Ohmiti K., Cavassini M. et al., 2013. Plos Pathogens, 9 (7) pp. e1003423.
Functional avidity: a measure to predict the efficacy of effector T cells?
Viganò S., Utzschneider D.T., Perreau M., Pantaleo G., Zehn D., Harari A., 2012. Clinical and Developmental Immunology, 2012 p. 153863. Peer-reviewed.
 
Modulation of human memory T-cell function by different antigen-presenting cells.
Perreau M., Welles H.C., Harari A., Calandra T., Roger T., Pantaleo G., 2012. European Journal of Immunology, 42 (3) pp. 799-802.
 
Mycobacterium tuberculosis-specific CD8 T cells are functionally and phenotypically different between latent infection and active disease
Rozot V., Vigano S., Mazza-Stalder J., Perreau M., Goletti D., Bart P. A., Nicod L., Pantaleo G., Harari A., 2012. p. 598 dans European Congress of Immunology, Immunology.
 
The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.
Perreau M., Welles H.C., Pellaton C., Gjoksi B., Potin L., Martin R., Harari A., Bett A., Casimiro D., Gall J. et al., 2012. Journal of Virology, 86 (11) pp. 6279-6285.
 
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.
Harari A., Rozot V., Bellutti Enders F., Perreau M., Mazza-Stalder J.M., Nicod L.P., Cavassini M., Calandra T., Blanchet C.L., Jaton K. et al., 2011/03. Nature medicine, 17 (3) pp. 372-376. Peer-reviewed.
 
DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa
Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P., Kremer E.J., Tartaglia J. et al., 2011. pp. A3 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
 
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.
Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P.A., Kremer E.J., Tartaglia J. et al., 2011. Journal of Virology, 85 (19) pp. 9854-9862.
 
Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns.
Giannoni E., Guignard L., Knaup Reymond M., Perreau M., Roth-Kleiner M., Calandra T., Roger T., 2011. Infection and Immunity, 79 (7) pp. 2690-2698.
 
Impact of Pre-Existing Immunity on the Selection of Rare Adenovirus Vector Candidates: Implications for HIV Vaccine Development
Perreau M., Welles H.C., Harari A., Potin L., Martin R., Bibert S., Roger T., Calandra T., Bett A., Gall J. et al., 2011. pp. A109 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
 
La signature immunologique - Nouvel outil diagnostique de la tuberculose active  [Immunological signatures: a new tool to diagnose active tuberculosis disease?].
Rozot V., Perreau M., Harari A., Pantaleo G., 2011. Médecine Sciences, 27 (10) pp. 808-811.
 
Control of the proliferation of activated CD4+ T cells by connexins.
Oviedo-Orta E., Perreau M., Evans W.H., Potolicchio I., 2010. Journal of Leukocyte Biology, 88 (1) pp. 79-86.
 
Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression.
Cellerai C., Perreau M., Rozot V., Enders F.B., Pantaleo G., Harari A., 2010. Journal of Virology, 84 (8) pp. 3868-3878.
 
The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution.
Seiradake E., Henaff D., Wodrich H., Billet O., Perreau M., Hippert C., Mennechet F., Schoehn G., Lortat-Jacob H., Dreja H. et al., 2009. Plos Pathogens, 5 (1) pp. e1000277. Peer-reviewed.
Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.
Perreau M., Pantaleo G., Kremer E.J., 2008. Journal of Experimental Medicine, 205 (12) pp. 2717-2725. Peer-reviewed.
 
Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy.
Perreau M., Mennechet F., Serratrice N., Glasgow J.N., Curiel D.T., Wodrich H., Kremer E.J., 2007. Journal of Virology, 81 (7) pp. 3272-3284. Peer-reviewed.
 
Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer.
Perreau M., Guérin M.C., Drouet C., Kremer E.J., 2007. Molecular Therapy, 15 (11) pp. 1998-2007. Peer-reviewed.
 
The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy.
Perreau M., Kremer E.J., 2006. Molecular Biotechnology, 34 (2) pp. 247-256.
 
Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus.
Perreau M., Kremer E.J., 2005. Journal of Virology, 79 (23) pp. 14595-14605. Peer-reviewed.
 
gp120-mediated induction of the MAPK cascade is dependent on the activation state of CD4(+) lymphocytes.
Kinet S., Bernard F., Mongellaz C., Perreau M., Goldman F.D., Taylor N., 2002. Blood, 100 (7) pp. 2546-2553. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University